NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Apnimed

Apnimed

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://apnimed.com/

Last Round

Debt

Mar 27, 2026

Total Funding Raised

$227.75M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Apnimed is a pharmaceutical company that develops novel oral therapies for the treatment of obstructive sleep apnea and other sleep-related breathing diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery, Medical Devices, Patient Engagement

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

obstructive sleep apneaOSAoral pharmacologic therapysleep apnea pillAD109CPAP alternativenew drug applicationNDAclinical-stage pharmaceuticaldigital health monitoringwearable medical devicepatient adherencesleep medicinebiotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Apnimed Comps

Public and private peers based on sector, stage, and business model.

Apnimed comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Apnimed Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
DebtMar 27, 2026
Early FundingOct 7, 2025
IPO AnnouncedJun 6, 2025
Series C ExtensionJan 3, 2023
Series CMay 4, 2022
Series B
Mar 25, 2021

Key People

Founding team and executive leadership

Luigi Taranto Montemurro

Chief Scientific Officer

Executive Team

Apnimed Investors

Notable investors and investment history

Apnimed investors
InvestorRounds
AmeripriseSeries B
HealthCare Royalty PartnersDebt
Columbia Threadneedle InvestmentsSeries C Extension
Morningside VenturesSeries C, Series A, Series B
J. & W. Seligman & CompanySeries C, Series B
SectoralSeries C, Series C Extension
Morningside GroupSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 1, 2026

    Job posting indicates AD109 is preparing for launch.

  • Mar 27, 2026

    $25M debt round raised.

Apnimed Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Apnimed Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Apnimed's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range89
Year Founded2017
Last FundingMar 27, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.